Joincare Pharmaceutical Group Industry Co Ltd 2024 AR2
The report highlights Joincare's operational resilience in 2024, achieving total revenues of RMB 15.619 billion and a net profit of RMB 1.387 billion. The company accelerated its transition from generics to innovation, advancing over 20 innovative drug projects across key therapeutic areas, with Pixavir Marboxil submitting its NDA. Joincare also integrated trillion-parameter-level AI models like DeepSeek-R1 into its core operations to enhance R&D efficiency. Additionally, the company maintained its AA rating in the MSCI ESG Ratings and was included in the S&P Global Sustainability Yearbook.
Company: Joincare Pharmaceutical Group Industry Co Ltd
Sector: Health Care
Country: China
Year: 2024
Type: AR2
Pages: 308
Joincare Pharmaceutical Group Industry Co Ltd
Annual Report
The report highlights Joincare's operational resilience in 2024, achieving total revenues of RMB 15.619 billion and a net profit of RMB 1.387 billion. The company accelerated its transition from generics to innovation, advancing over 20 innovative drug projects across key therapeutic areas, with Pixavir Marboxil submitting its NDA. Joincare also integrated trillion-parameter-level AI models like DeepSeek-R1 into its core operations to enhance R&D efficiency. Additionally, the company maintained its AA rating in the MSCI ESG Ratings and was included in the S&P Global Sustainability Yearbook.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees